Abstract
Several experimental autoimmune diseases (AID), including allergic encephalomyelitis, ie the multiple sclerosis (MS) model, respond to TBI and chemotherapy followed by BMT. Remissions of AID may also occur in patients with concomitant malignancies treated with allogeneic or autologous BMT. These observations have emphasized the possibility of treating AID with high-dose therapy and haematopoietic stem cell transplantation (HSCT). In a phase I/II pilot study, 15 patients with progressive MS were treated with BEAM followed by autologous blood SCT and antithymocyte globulin (ATG). Patients were severely disabled, with median EDSS and SNRS scores of 6 (5–7.5) and 42 (33–62), respectively. Cyclophosphamide (4 g/m2) and G/GM-CSF (5 μ g/kg/day) were used for stem cell mobilization, which caused no neurotoxicity. On days +1 and +2, ATG (2.5–5 mg/kg) was given for in vivo T cell-depletion. Allergy (93%) and infections (87%) were the principal toxic complications. Mild, transient, neurotoxicity was observed in six patients in the immediate post-transplant period. The median follow-up time is 6 months (6–18). Durable neurologic improvements have been detected on both the EDSS (7/15) and SNRS (15/15) systems. One patient worsened at 3 months and two have relapsed. Autologous HSCT appears feasible in MS; it does not aggravate disability and seems to offer a clinical benefit. However, these observations need confirmation and long-term outcomes will show if benefits counterbalance toxicity and cost.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fassas, A., Anagnostopoulos, A., Kazis, A. et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 20, 631–638 (1997). https://doi.org/10.1038/sj.bmt.1700944
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700944
Keywords
This article is cited by
-
Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
Lipids in Health and Disease (2023)
-
Multiple Sklerose: Stillstand durch Interventionen
Der Nervenarzt (2022)
-
The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis
Journal of Neurology (2022)
-
Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis
Journal of Neurology (2022)
-
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
Cellular & Molecular Immunology (2021)